166 related articles for article (PubMed ID: 15673949)
1. Comparison of endoscopic gastric mucosa features after administration of piroxicam to meloxicam and their correlation with dyspepsia symptoms in elderly patient with knee osteoarthritis.
Girawan D; Abdurachman SA; Djumhana A; Roslia J; Pramudiyo R
Acta Med Indones; 2004; 36(4):202-6. PubMed ID: 15673949
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study.
Lipscomb GR; Wallis N; Armstrong G; Rees WD
Br J Clin Pharmacol; 1998 Aug; 46(2):133-7. PubMed ID: 9723821
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis.
Chang DM; Young TH; Hsu CT; Kuo SY; Hsieh TC
Clin Rheumatol; 2001; 20(2):104-13. PubMed ID: 11346221
[TBL] [Abstract][Full Text] [Related]
4. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers.
Patoia L; Santucci L; Furno P; Dionisi MS; Dell'Orso S; Romagnoli M; Sattarinia A; Marini MG
Br J Rheumatol; 1996 Apr; 35 Suppl 1():61-7. PubMed ID: 8630640
[TBL] [Abstract][Full Text] [Related]
5. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.
Dequeker J; Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Isomäki H; Littlejohn G; Mau J; Papazoglou S
Br J Rheumatol; 1998 Sep; 37(9):946-51. PubMed ID: 9783758
[TBL] [Abstract][Full Text] [Related]
6. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip.
Lindén B; Distel M; Bluhmki E
Br J Rheumatol; 1996 Apr; 35 Suppl 1():35-8. PubMed ID: 8630634
[TBL] [Abstract][Full Text] [Related]
7. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial.
Dougados M; Gueguen A; Nakache JP; Velicitat P; Veys EM; Zeidler H; Calin A
Rheumatology (Oxford); 1999 Mar; 38(3):235-44. PubMed ID: 10325662
[TBL] [Abstract][Full Text] [Related]
8. Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis.
Ghozlan PR; Bernhardt M; Vélicitat P; Bluhmki E
Br J Rheumatol; 1996 Apr; 35 Suppl 1():51-5. PubMed ID: 8630638
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study.
Carrabba M; Paresce E; Angelini M; Galanti A; Marini MG; Cigarini P
Curr Med Res Opin; 1995; 13(6):343-55. PubMed ID: 8829892
[TBL] [Abstract][Full Text] [Related]
10. Review of clinical trials and benefit/risk ratio of meloxicam.
Barner A
Scand J Rheumatol Suppl; 1996; 102():29-37. PubMed ID: 8628979
[TBL] [Abstract][Full Text] [Related]
11. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam.
Tavakoli M
Pharmacoeconomics; 2003; 21(6):443-54. PubMed ID: 12678570
[TBL] [Abstract][Full Text] [Related]
12. Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogs.
Forsyth SF; Guilford WG; Haslett SJ; Godfrey J
J Small Anim Pract; 1998 Sep; 39(9):421-4. PubMed ID: 9791828
[TBL] [Abstract][Full Text] [Related]
13. Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens.
Santucci L; Fiorucci S; Patoia L; Di Matteo FM; Brunori PM; Morelli A
Dig Dis Sci; 1995 Sep; 40(9):2074-80. PubMed ID: 7555467
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory activity of silymarin in patients with knee osteoarthritis. A comparative study with piroxicam and meloxicam.
Hussain SA; Jassim NA; Numan IT; Al-Khalifa II; Abdullah TA
Saudi Med J; 2009 Jan; 30(1):98-103. PubMed ID: 19139781
[TBL] [Abstract][Full Text] [Related]
15. Gastric damage induced by subchronic administration of preferential cyclooxygenase-1 and cyclooxygenase-2 inhibitors in rats.
Villegas I; Alarcón de la Lastra C; Martín MJ; Motilva V; La Casa García C
Pharmacology; 2002 Oct; 66(2):68-75. PubMed ID: 12207113
[TBL] [Abstract][Full Text] [Related]
16. Meloxicam in acute episodes of soft-tissue rheumatism of the shoulder.
Vidal L; Kneer W; Baturone M; Sigmund R
Inflamm Res; 2001 Mar; 50 Suppl 1():S24-9. PubMed ID: 11339517
[TBL] [Abstract][Full Text] [Related]
17. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam.
Singh G; Lanes S; Triadafilopoulos G
Am J Med; 2004 Jul; 117(2):100-6. PubMed ID: 15234645
[TBL] [Abstract][Full Text] [Related]
18. Safety of meloxicam: a global analysis of clinical trials.
Distel M; Mueller C; Bluhmki E; Fries J
Br J Rheumatol; 1996 Apr; 35 Suppl 1():68-77. PubMed ID: 8630641
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease.
Degner F; Sigmund R; Zeidler H
Clin Ther; 2000 Apr; 22(4):400-10. PubMed ID: 10823362
[TBL] [Abstract][Full Text] [Related]
20. Mucosal damage induced by preferential COX-1 and COX-2 inhibitors: role of prostaglandins and inflammatory response.
Villegas I; La Casa C; de la Lastra CA; Motilva V; Herrerías JM; Martín MJ
Life Sci; 2004 Jan; 74(7):873-84. PubMed ID: 14659976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
